{"id":347088,"date":"2026-11-14T13:27:49","date_gmt":"2026-11-14T07:57:49","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/medicamen-biotech-q2-results-fy27-pat-2-crore\/"},"modified":"2026-11-14T13:27:49","modified_gmt":"2026-11-14T07:57:49","slug":"medicamen-biotech-q2-results-fy27-pat-2-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/medicamen-biotech-q2-results-fy27-pat-2-crore\/","title":{"rendered":"Medicamen Biotech Q2 Results FY27: Revenue Up 10.18% to Rs 46.53 Cr, PAT Rises to Rs 2.35 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Medicamen Biotech Q2 Results FY27 were declared on 13 November 2026 on a Standalone basis for the July to September 2026 quarter. Revenue came in at Rs 46.53 Cr, up 10.18% YoY, while net profit stood at Rs 2.35 Cr, up 6.33% YoY. These standalone results also show Operating Profit of Rs 5.92 Cr, and the YoY growth in Operating Profit was ahead of the growth in revenue.<\/p>\n<\/div>\n

Medicamen Biotech Ltd<\/a> (MEDICAMEQ) Q2 Results FY27 announced on 13 November 2026, covering the company’s financial performance for the July to September quarter. The Standalone figures show revenue of Rs 46.53 Cr against Rs 42.23 Cr a year earlier and PAT of Rs 2.35 Cr against Rs 2.21 Cr. This Medicamen Biotech Q2 Results FY27 report is built around that results date and the Standalone results basis.<\/p>\n

This Medicamen Biotech Q2 Results results analysis covers the financial highlights, the business drivers, the FY27 outlook and the risks that the disclosed data brings up. The Financial Highlights table that follows places the three profit and revenue lines side by side.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n